panitumumab
takeda,amgen
['improve ', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
#asco22 | the #improve trial met its primary endpoint with the intermittent folfiri-pani strategy producing a long pfs with a reduced skin toxicity. a comment by antonio avallone. #mcrc 
Latest research in oncology | Breaking news, insights, interviews, live tweeting and updates from major conferences | Published by @ilpensiero | @think2it